Putative role of the adenosine A3 receptor in the antiproliferative action of N6-(2-isopentenyl)adenosine

Purinergic Signalling

Volumn 7, Issue 4, 2011, Pages 453-462

  Blad, Clara C ^a   von Drabbe Künzel, Jacobien K Frijtag ^a   de Vries, Henk ^a   Mulder Krieger, Thea ^a   Bar Yehuda, Sara ^b   Fishman, Pnina ^b   IJzerman, Adriaan P ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b Can Fite BioPharma Ltd   (Israel)

Author keywords

Adenosine A3 receptor; Antitumor agent; HPLC; Modified nucleoside; N6 (2 isopentenyl)adenosine (IPA); Zeatin riboside

Indexed keywords

EID: 81955161193     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-011-9244-9     Document Type: Article

References (40)

1. 3 adenosine receptor. Proc Natl Acad Sci USA 89(16): 7432-7436.
2. 3 adenosine receptor. Biochim Biophys Acta 1179(1): 105-107.
3. 3 adenosine receptor. Proc Natl Acad Sci USA 90(21): 10365-10369.
4. Fishman P, Bar-Yehuda S, Synowitz M, Powell JD, Klotz KN, Gessi S, Borea PA (2009) Adenosine receptors and cancer. Handb Exp Pharmacol 193: 399-441. doi: 10. 1007/978-3-540-89615-9_14.
5. Gessi S, Cattabriga E, Avitabile A, Gafa R, Lanza G, Cavazzini L, Bianchi N, Gambari R, Feo C, Liboni A, Gullini S, Leung E, Mac-Lennan S, Borea PA (2004) Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin Cancer Res 10(17): 5895-5901.
6. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Borea PA (2005) A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J Biol Chem 280(20): 19516-19526.
7. Varani K, Maniero S, Vincenzi F, Targa M, Stefanelli A, Maniscalco P, Martini F, Tognon M, Borea PA (2011) A3 receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt/nuclear factor-kappaB pathway. Am J Respir Crit Care Med 183(4): 522-530.
8. Fishman P, Bar-Yehuda S, Vagman L (1998) Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth. Cancer Res 58(14): 3181-3187.
9. 3 adenosine receptors. J Cell Physiol 183(3): 393-398.
10. Fishman P, Bar-Yehuda S, Barer F, Madi L, Multani AS, Pathak S (2001) The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res 269(2): 230-236.
11. 3 adenosine receptor agonist, in healthy young men. Int J Clin Pharmacol Ther 42(10): 534-542.
12. Bar-Yehuda S, Stemmer SM, Madi L, Castel D, Ochaion A, Cohen S, Barer F, Zabutti A, Perez-Liz G, Del Valle L, Fishman P (2008) The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappa B signal transduction pathways. Int J Oncol 33(2): 287-295.
13. 3 adenosine receptor agonists. Neoplasia 3(2): 125-131.
14. 3 adenosine receptor. Biochem Pharmacol 79(1): 48-56. doi: 10. 1016/j. bcp. 2009. 07. 024.
15. 3 adenosine receptors. Biochem Pharmacol 65(4): 525-534.
16. van Veldhoven JPD, Chang LCW, von Frijtag Drabbe Künzel JK, Mulder-Krieger T, Struensee-Link R, Beukers MW, Brussee J, IJzerman AP (2008) A new generation of adenosine receptor antagonists: From di- to trisubstituted aminopyrimidines. Bioorg Med Chem 16(6): 2741-2752.
17. 3 adenosine receptors. Biochem Pharmacol 65(10): 1675-1684. doi: 10. 1016/s0006-2952(03)00153-9.
18. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M (1994) Nomenclature and classification of purinoceptors. Pharmacol Rev 46(2): 143-156.
19. Yan L, Burbiel JC, Maass A, Muller CE (2003) Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs 8(2): 537-576.
20. Fredholm BB, Irenius E, Kull B, Schulte G (2001) Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 61(4): 443-448.
21. 3 receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. Mol Pharmacol 58(3): 477-482.
22. 6-isopentenyladenosine: a potential therapeutic agent for a variety of epithelial cancers. Int J Cancer 120(12): 2744-2748. doi: 10. 1002/ijc. 22601.
23. 6-(delta2-isopentenyl)adenosine, a natural component of mammalian transfer RNA. Cancer Res 30(5): 1429-1436.
24. Mittelman A, Evans JT, Chheda GB (1975) Cytokinins as chemotherapeutic agents. Ann N Y Acad Sci 255(AUG8): 225-234.
25. 6-isopentenyladenosine: an emerging anticancer drug. Anticancer Agents Med Chem 8(2): 200-204.
26. 3 adenosine receptor. J Cell Physiol 186(1): 19-23.
27. 3 adenosine receptor antagonists. J Med Chem 41(17): 3186-3201. doi: 10. 1021/jm980093j.
28. Kim SG, Ravi G, Hoffmann C, Jung Y-J, Kim M, Chen A, Jacobson KA (2002) p53-Independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, Cl-IB-MECA. Biochem Pharmacol 63(5): 871-880.
29. Lu J, Pierron A, Ravid K (2003) An adenosine analogue, IB-MECA, down-regulates estrogen receptor and suppresses human breast cancer cell proliferation. Cancer Res 63(19): 6413-6423.
30. Morello S, Petrella A, Festa M, Popolo A, Monaco M, Vuttariello E, Chiappetta G, Parente L, Pinto A (2008) Cl-IB-MECA inhibits human thyroid cancer cell proliferation independently of A3 adenosine receptor activation. Cancer Biol Ther 7(2): 278-284.
31. 6-(2-isopentenyl)adenosine metabolism in man. Biochem Pharmacol 21(1): 27-37.
32. Sakakibara H (2006) Cytokinins: activity, biosynthesis, and translocation. Annu Rev Plant Biol 57: 431-449. doi: 10. 1146/annurev. arplant. 57. 032905. 105231.
33. Skoog F, Armstrong DJ (1970) Cytokinins. Annu Rev Plant Physiol 21: 359-384.
34. 6-(delta2-isopentenyl) adenosine. A component of transfer ribonucleic acid of yeast and of mammalian tissue methods of isolation and characterization. Biochemistry 6(6): 1837-1848.
35. Burns DM, Rodi CP, Agris PF (1976) Natural occurrence of an inhibitor of mammalian cell growth in human and mouse cell lines of normal and tumor origin. Cancer Biochem Biophys 1(6): 269-280.
36. 6-(delta-2-isopentenyl)adenosine, and 2′-O-methylguanosine as determined by radioimmunoassay for normal subjects and cancer-patients. Cancer Res 42(12): 5265-5269.
37. Ravi V, Nascar SK, Makeshkumar T, Binoy Babu, Prakash Krishnan BS (2009) Molecular physiology of storage root formation and development in sweet potato (Ipomoea batatas (L.) Lam.). J Root Crops 35(1): 1-27.
38. Suttle JC (1998) Postharvest changes in endogenous cytokinins and cytokinin efficacy in potato tubers in relation to bud endodormancy. Physiol Plant 103(1): 59-69.
39. Klaasse EC, IJzerman AP, de Grip WJ, Beukers MW (2008) Internalization and desensitization of adenosine receptors. Purinergic Signal 4(1): 21-37. doi: 10. 1007/s11302-007-9086-7.
40. 3 adenosine receptor is highly expressed in tumor versus normal cells. Clin Cancer Res 10(13): 4472-4479. doi: 10. 1158/1078-0432. ccr-03-0651.